JP2013526545A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526545A5
JP2013526545A5 JP2013510313A JP2013510313A JP2013526545A5 JP 2013526545 A5 JP2013526545 A5 JP 2013526545A5 JP 2013510313 A JP2013510313 A JP 2013510313A JP 2013510313 A JP2013510313 A JP 2013510313A JP 2013526545 A5 JP2013526545 A5 JP 2013526545A5
Authority
JP
Japan
Prior art keywords
formulation
use according
days
injection
methotrexate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013510313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526545A (ja
JP5980775B2 (ja
Filing date
Publication date
Priority claimed from US12/914,944 external-priority patent/US9770414B2/en
Application filed filed Critical
Publication of JP2013526545A publication Critical patent/JP2013526545A/ja
Publication of JP2013526545A5 publication Critical patent/JP2013526545A5/ja
Application granted granted Critical
Publication of JP5980775B2 publication Critical patent/JP5980775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013510313A 2010-05-13 2011-05-12 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 Active JP5980775B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33454610P 2010-05-13 2010-05-13
US61/334,546 2010-05-13
US12/914,944 2010-10-28
US12/914,944 US9770414B2 (en) 2010-05-13 2010-10-28 Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
PCT/US2011/036328 WO2011143484A1 (en) 2010-05-13 2011-05-12 A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015188829A Division JP6263508B2 (ja) 2010-05-13 2015-09-25 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤

Publications (3)

Publication Number Publication Date
JP2013526545A JP2013526545A (ja) 2013-06-24
JP2013526545A5 true JP2013526545A5 (enExample) 2014-06-26
JP5980775B2 JP5980775B2 (ja) 2016-08-31

Family

ID=44911988

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013510313A Active JP5980775B2 (ja) 2010-05-13 2011-05-12 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
JP2015188829A Active JP6263508B2 (ja) 2010-05-13 2015-09-25 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
JP2017013045A Withdrawn JP2017071652A (ja) 2010-05-13 2017-01-27 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015188829A Active JP6263508B2 (ja) 2010-05-13 2015-09-25 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
JP2017013045A Withdrawn JP2017071652A (ja) 2010-05-13 2017-01-27 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤

Country Status (6)

Country Link
US (3) US9770414B2 (enExample)
EP (1) EP2568962B1 (enExample)
JP (3) JP5980775B2 (enExample)
CN (1) CN103002877B (enExample)
IL (1) IL222683B (enExample)
WO (1) WO2011143484A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2846773A4 (en) 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
HUE062466T2 (hu) 2012-07-05 2023-11-28 Taiwan Liposome Co Ltd Eljárások arthritis kezelésére
JPWO2015147018A1 (ja) * 2014-03-28 2017-04-13 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤
WO2015183213A1 (en) * 2014-05-28 2015-12-03 Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid
ES2969374T3 (es) 2014-07-30 2024-05-17 Massachusetts Eye & Ear Infirmary Metotrexato para la vitreorretinopatía proliferativa
JP5774190B1 (ja) * 2014-12-12 2015-09-09 ジーンメディカル株式会社 皮下注射用剤及び皮下注射用剤を含有する注射器の製造方法
KR102496871B1 (ko) * 2014-12-12 2023-02-07 주식회사 모테조 피하 주사용제
EP3317448B1 (en) 2015-06-30 2021-09-08 Tela Bio, Inc. Corner-lock stitch patterns
US10426587B2 (en) 2015-07-21 2019-10-01 Tela Bio, Inc. Compliance control stitching in substrate materials
KR20230161532A (ko) 2015-11-24 2023-11-27 메사추세츠 인스티튜트 오브 테크놀로지 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법
EP3448308B1 (en) 2016-04-26 2024-08-14 Tela Bio, Inc. Hernia repair grafts having anti-adhesion barriers
WO2018031980A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
CN120939250A (zh) 2016-08-12 2025-11-14 L.E.A.F.控股集团公司 聚谷氨酸化抗叶酸剂及其用途
WO2018031967A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
KR102869711B1 (ko) 2016-11-17 2025-10-15 코그니토 쎄라퓨틱스, 인코포레이티드 시각 자극을 통한 신경 자극 방법 및 시스템
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
AU2018347870B2 (en) 2017-10-10 2022-12-08 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
JP7416700B2 (ja) 2017-11-14 2024-01-17 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法
CN115475142A (zh) * 2017-11-20 2022-12-16 平顶山学院 一种口服甲氨蝶呤脂质体及其制备方法
US12246019B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
CA3090506A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
EP3749313A4 (en) 2018-02-07 2022-03-16 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE ANTIFOLATES AND ASSOCIATED USES
CN111954530A (zh) * 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 γ聚谷氨酸化培美曲塞及其用途
JP7490240B2 (ja) * 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用
US12239734B2 (en) 2018-02-07 2025-03-04 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
WO2019157138A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
JP7491573B2 (ja) * 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
CN111936145A (zh) * 2018-02-14 2020-11-13 L.E.A.F.控股集团公司 γ聚谷氨酸化氨甲蝶呤及其用途
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
EP3755335A4 (en) 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
US11590262B2 (en) 2018-03-09 2023-02-28 Tela Bio, Inc. Surgical repair graft
WO2020185688A1 (en) 2019-03-08 2020-09-17 Tela Bio, Inc. Textured medical textiles
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
US20240374599A1 (en) 2020-02-26 2024-11-14 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
US20230173295A1 (en) * 2020-04-23 2023-06-08 Massachusetts Institute Of Technology Systems, Devices, and Methods for Gamma Entrainment using Sensory Stimuli to Alleviate Cognitive Deficits and/or Neuroinflammation Induced by Chemotherapy Agents
CN114249731B (zh) * 2020-09-24 2023-09-29 南京海润医药有限公司 一种甲氨蝶呤中间体的精制方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
NZ237464A (en) * 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
RO116341B1 (ro) 1993-11-16 2001-01-30 Depotech Corp La Jolia Lipozom multivezicular si procedeu de obtinere a acestuia
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6306432B1 (en) * 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
EP1028629A4 (en) * 1997-11-05 2003-06-04 Biozone Lab Inc IMPROVED FOOD PREPARATION FOR INFANTS CONTAINING NUTRIENTS AND ACTIVE SUBSTANCES ENCLOSED IN LIPOSOMES
JP4575592B2 (ja) 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
JP4868698B2 (ja) * 2001-05-02 2012-02-01 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20040176381A1 (en) * 2003-03-06 2004-09-09 Walsh Michael J. Methotrexate compliance packaging
US6921667B2 (en) * 2003-03-07 2005-07-26 Prometheus Laboratories, Inc. Methods for direct detection of individual methotrexate metabolites
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
JP2008512490A (ja) 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
WO2006122414A1 (en) 2005-05-17 2006-11-23 Matregen Corp. Depot for sustained and controlled delivery of methotrexate
US20070009434A1 (en) * 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
WO2007134819A1 (en) * 2006-05-18 2007-11-29 Medigene Ag Cationic liposomal preparations for the treatment of rheumatoid arthritis
DE102006033837A1 (de) 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
US20080075807A1 (en) * 2006-09-22 2008-03-27 Baldwin Cheryl J Methods Of Fortifying Foods With Vitamin D And Food Products Thereof
GB2443738A (en) 2006-11-09 2008-05-14 Proprius Pharmaceuticals Inc A sustained release methotrexate composition and methods of use thereof
US8329220B2 (en) 2007-08-24 2012-12-11 Aegis Therapeutics, Llc Controlled release formulations
MX2010007393A (es) * 2008-01-03 2010-11-09 Abbott Biotech Ltd Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.

Similar Documents

Publication Publication Date Title
JP2013526545A5 (enExample)
US9770414B2 (en) Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
EP3964200A1 (en) Compositions and methods for delivery of therapeutic agents
JP2015523355A5 (enExample)
RU2014120216A (ru) Комбинационные липосомальные композиции для лечения рака
JP2015515992A5 (enExample)
FI3821887T3 (fi) Mitoksantroni liposomin käyttö ei-hodgkinin lymfooman hoitoon
RU2015103538A (ru) Способы лечения артрита
CL2013003621A1 (es) Composición farmacéutica inhalable que comprende una dispersión de partículas liposomales que contienen un agente bioactivo hidrófobo, tal como coq10, un fosfolípido, y un vehículo de dispersión acuosa, apta para aerosolización continua; método de preparación; método de administración; uso para tratar enfermedades del pulmón.
JP2017517533A5 (enExample)
TWI660749B (zh) 設計脂質體水相和非水相部分的組成來控制藥物的釋放趨勢
CA2856646A1 (en) Combination treatment of cancer
JP2016513651A5 (enExample)
BR112015022476A2 (pt) composições de oxaliplatina de lipossoma para terapia de câncer
RU2019111096A (ru) Лекарственные формы леводопы для быстрого купирования болезни паркинсона
JP5700909B2 (ja) パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
JP2017516829A5 (enExample)
NZ700472A (en) Use of vesicular formations in the manufacture of a medicament for treating rosacea
JP2015500840A5 (enExample)
JP2022088622A (ja) がん療法のためのメトロノミック経口ゲムシタビン
EA027506B1 (ru) Способ лечения рака молочной железы
HK40070194A (en) Compositions and methods for delivery of therapeutic agents
US20240358639A1 (en) Nanoparticles for cancer treatment
JPWO2020056102A5 (enExample)
RU2021102771A (ru) Применение липосомы митоксантрона для лечения неходжкинской лимфомы